Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Goodyear Tire & Rubber Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Goodyear Tire & Rubber Co trades at $6.69 (market cap $1.91B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.2× Goodyear Tire & Rubber Co's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| BIO | GT | |
|---|---|---|
Market Cap | $8.04B | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $11.54 |
52-Week Low | $241.71 | $5.58 |
Enterprise Value | $7.85B | $9.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Goodyear Tire & Rubber (GT) trades at $6.64, down 2.5% today, with a bearish technical signal and mixed quarterly earnings. The stock shows deep value metrics with a P/E of 4.69 and P/B of 0.64, but fundamental weakness persists with negative net income margin of -11.64% and ROE of -52.56%. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering to strengthen liquidity.
The outlook remains challenging due to operational headwinds and declining revenue, though analyst consensus suggests 32% upside to the $8.75 price target. Key risks include sustained profitability issues and high debt, while potential catalysts include cost-saving initiatives and new contracts like NASA's lunar tire supply.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
